Please login to the form below

Not currently logged in


This page shows the latest CT-P59 news and features for those working in and with pharma, biotech and healthcare.

Celltrion’s investigational mAb cuts COVID-19 recovery time

Celltrion’s investigational mAb cuts COVID-19 recovery time

Participants were randomised to receive either CT-P59 40 mg/kg, CT-P59 80mg/kg or placebo. ... In addition, CT-P59 treated patients also ‘rapidly and significantly’ reduced viral load through day seven of treatment compared to placebo.

Latest news

  • Celltrion launches phase 3 trial of COVID-19 mAb Celltrion launches phase 3 trial of COVID-19 mAb

    In September, Celltrion also announced interim results from a phase 1 clinical trial of CT-P59, which showed a promising safety, tolerability and pharmacokinetics profile for the drug. ... In this early phase study, CT-P59 also demonstrated no

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...